This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n7http://linked.opendata.cz/resource/drugbank/drug/DB00546/identifier/pubchem-substance/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00546/identifier/kegg-drug/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00546/identifier/drugbank/
n10http://linked.opendata.cz/resource/mesh/concept/
n18http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00546/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n6http://linked.opendata.cz/resource/drugbank/drug/DB00546/identifier/chebi/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00546/identifier/wikipedia/
n9http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00546/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00546/identifier/pubchem-compound/
n20http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00546
rdf:type
n3:Drug
n3:description
Adinazolam (Deracyn®) is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolam was developed by Dr. Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed. Adinazolam was never FDA approved and was never available to the public.
n3:generalReferences
# Lahti RA, Sethy VH, Barsuhn C, Hester JB: Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology. 1983 Nov;22(11):1277-82. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6320036 # Sethy VH, Collins RJ, Daniels EG: Determination of biological activity of adinazolam and its metabolites. J Pharm Pharmacol. 1984 Aug;36(8):546-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6148400 # File SE, Pellow S: Triazolobenzodiazepines antagonize the effects of anxiogenic drugs mediated at three different central nervous system sites. Neurosci Lett. 1985 Oct 24;61(1-2):115-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2867497
n3:group
approved
n3:halfLife
Less than 3 hours.
n3:indication
For the treatment of anxiety and status epilepticus.
owl:sameAs
n16:DB00546 n18:DB00546
dcterms:title
Adinazolam
adms:identifier
n6:251412 n7:46509054 n8:D02770 n11:37632 n12:34519 n13:DB00546 n14:PA164783813 n17:Adinazolam
n3:mechanismOfAction
Adinazolam binds to peripheral-type benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.
n3:synonym
8-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-S-triazolo(4,3-a)(1,4)benzodiazepine Adinazolamum
n3:toxicity
Signs of overdose may include muscle weakness, ataxia, dysarthria and particularly in children paradoxical excitement. In more severe cases diminished reflexes, confusion, and coma may ensue.
n9:hasConcept
n10:M0118624
n3:IUPAC-Name
n4:271B43E4-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B43EA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B43E9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B43E6-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B43E7-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B43E8-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B43E2-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B43E0-363D-11E5-9242-09173F13E4C5 n4:271B43E3-363D-11E5-9242-09173F13E4C5 n4:271B43FA-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B43E1-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:N05BA07
n3:H-Bond-Acceptor-Count
n4:271B43F0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B43F1-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B43EB-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B43EC-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B43EE-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B43ED-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B43EF-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
37115-32-5
n3:category
n3:Bioavailability
n4:271B43F6-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B43F8-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B43F9-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B43F5-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B43F4-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B43F7-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B43E5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B43F2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B43F3-363D-11E5-9242-09173F13E4C5